2024-12-13 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a leading healthcare company developing and manufacturing pharmaceutical, medical device, and consumer health products, significantly underperformed the S&P 500 (VOO) over the given period.  The cumulative return for JNJ was 25.36%, while VOO's was 122.07%. This represents a difference of -96.7%, indicating JNJ's substantial underperformance relative to the broader market.  The provided relative divergence metric of 0.0 suggests this underperformance is at the lowest end of the historical range observed.


**2. Recent Price Movement:**

* **Closing Price:** $146.64 (Last market: $146.34)
* **5-Day Moving Average:** $148.86
* **20-Day Moving Average:** $152.11
* **60-Day Moving Average:** $157.27

The stock price is currently below all three moving averages, suggesting a downtrend.  The recent closing price is only slightly higher than the last market price, indicating minimal price movement.


**3. Technical Indicators and Expected Return:**

* **RSI (Relative Strength Index):** 30.61  This indicates the stock is in oversold territory, potentially suggesting a bounce is possible.
* **PPO (Percentage Price Oscillator):** -0.28 This negative value confirms the downtrend.
* **Recent Relative Divergence:** 0.0 (-) This points to a short-term downward trend.
* **Expected Return:** 0.0%  The provided expected return is 0%, suggesting no significant outperformance is anticipated against the S&P 500 over the long term (2+ years) based on this data.  Given the significant underperformance noted in point 1, this should be considered with caution.

A price of $146.34 does not trigger any significant price action alerts (no mention of rapid increase or decrease given this price).


**4. Recent Earnings Analysis:**

The provided earnings data shows inconsistent performance across quarters.  While revenue remains relatively stable around $21-22B, EPS fluctuates significantly.  There's no clear trend in revenue growth, and EPS is highly volatile.  Without access to expected values, we cannot determine whether any quarters were "beats" or "misses" relative to expectations.  The exceptionally high EPS of 10.32 in 2023-10-27 is an outlier requiring further investigation beyond the scope of the provided data.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, hovering around $22 Billion. Profit margins are consistently high, ranging between 68-70%, suggesting strong profitability.  However, there's no clear trend in either revenue or profit margins.

* **Capital and Profitability:** Equity fluctuates but generally remains around $70 Billion.  ROE (Return on Equity) exhibits considerable volatility, with a particularly high value of 36.54% in 2023-09-30 that needs further context. This erratic ROE makes it hard to draw conclusions about capital efficiency without additional information.


**6. News and Recent Issues:**

No news or recent market outlook, analyst opinions, or performance highlights were provided in the original prompt. This information would enhance the analysis significantly.


**7. Overall Analysis Summary:**

JNJ significantly underperformed the S&P 500 over the observed period.  While the company shows strong and stable revenue and high profit margins, its EPS is volatile and the ROE is erratic.  Technical indicators suggest the stock is oversold, but the overall trend is downward. The lack of recent news and detailed analyst opinions limits the overall depth of this analysis.  The exceptionally high ROE in 2023-09-30 and the outlier EPS in 2023-10-27 require further investigation for a complete picture.  The 0% expected return against the S&P 500 is concerning given the current underperformance, urging caution for long-term investors. Further research into the specific reasons for JNJ's underperformance and the outliers in the financial data is needed before any informed investment decisions can be made.

**8. Disclaimer:** This report is based solely on the limited data provided.  It does not constitute financial advice.  Independent research and consultation with a financial advisor are recommended before making any investment decisions.
